Green Cross pubish series of CB1 antagonists

Green Cross have published a series of biarylpyrazolyl oxadiazole based compounds as CB1 antagonists

KeyNeurotek receive EMEA Orphan Drug Designation for KN38-7271 in TBI

KeyNeurotek Pharmaceuticals have received Orphan Drug Designation for its lead cannabinoid agonist compound KN38-7271 for the treatment of moderate and severe closed traumatic brain injury from EMEA

University of Texas publsihes series for Cannabinoid CB2 agonists

Researchers at he University of Texas have published a series of cannabinoid receptor 2 (CB2) agonists for the treatment of neuropathic pain.

Glenmarks CB2 agonist GRC 10693 to enter phase I trials

Glenmark Pharmaceuticals have announced that its CB2 agonist GRC-10693 is entering Phase I trials for neuropathic, osteoarthritis and other inflammatory pain.

Watson Launch Generic Dronabinol

Watson have announced the launch of generic dronabinol under a supply agreement with Solvay Pharmaceuticals.

Pfizer to initiate Phase 1 Study Of CP-945598 In Patients With NASH

Pfizer are about to begin a Phase I study of Cannabinoid 1 antagonist CP-945598 In Patients With Nonalcoholic steatohepatitis (NASH)

Activation of the cannabinoid receptor may have use in Systemic Sclerosis

Data presented at EULAR show that treatment of fibroblasts from systemic sclerosis patients with a cannabinoid antagonist (WIN552122) reduces TGFbeta, CTGF and collagen type-I mRNA.

Rimonabant effective in Type 2 Diabetes

Clinical data presented at ADA show Sanofi-aventis’ CB1 antagonist rimonabant significantly improved glucose levels (as measured by HbA1c) compared to controls in patients with type 2 diabetes

Phase I results reported for Cannabinoid Agonist KN38-7271

Phase I results of KeyNeurotek’s cannabinoid receptor agonist KN38-7271 show all study endpoints to have been met and the drug shown to be safe and tolerable. KN38-7271 is being developed for the treatment of acute neurodegenerative incidents like a stroke and  traumatic brain injury